Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Toll-like Receptor 3 is a Therapeutic Target for Pulmonary Hypertension.

Farkas D, Thompson AAR, Bhagwani AR, Hultman S, Ji H, Kotha N, Farr G, Arnold ND, Braithwaite A, Casbolt H, Cole JE, Sabroe I, Monaco C, Cool CD, Goncharova EA, Lawrie A, Farkas L.

Am J Respir Crit Care Med. 2018 Sep 13. doi: 10.1164/rccm.201707-1370OC. [Epub ahead of print]

PMID:
30211629
2.

Divergent Roles for TRAIL in Lung Diseases.

Braithwaite AT, Marriott HM, Lawrie A.

Front Med (Lausanne). 2018 Jul 27;5:212. doi: 10.3389/fmed.2018.00212. eCollection 2018. Review.

3.

Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes.

Mehta SY, Morten BC, Antony J, Henderson L, Lasham A, Campbell H, Cunliffe H, Horsfield JA, Reddel RR, Avery-Kiejda KA, Print CG, Braithwaite AW.

Oncotarget. 2018 Jun 26;9(49):29146-29161. doi: 10.18632/oncotarget.25635. eCollection 2018 Jun 26.

4.

A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Kazantseva M, Mehta S, Eiholzer RA, Hung N, Wiles A, Slatter TL, Braithwaite AW.

Mamm Genome. 2018 Jul 10. doi: 10.1007/s00335-018-9758-3. [Epub ahead of print] Review.

PMID:
29992419
5.

Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.

Kazantseva M, Eiholzer RA, Mehta S, Taha A, Bowie S, Roth I, Zhou J, Joruiz SM, Royds JA, Hung NA, Slatter TL, Braithwaite AW.

J Pathol. 2018 Sep;246(1):77-88. doi: 10.1002/path.5111. Epub 2018 Jul 31.

6.

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.

Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, Kiely DG, Grimminger F, Ghofrani HA, Weissmann N, Seeger W, Lawrie A, Schermuly RT, Kojonazarov B.

BMC Pulm Med. 2018 Mar 2;18(1):41. doi: 10.1186/s12890-018-0604-x.

7.

Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response.

Zhang J, Burn C, Young K, Wilson M, Ly K, Budhwani M, Tschirley A, Braithwaite A, Baird M, Hibma M.

Sci Rep. 2018 Feb 5;8(1):2373. doi: 10.1038/s41598-018-20779-2.

8.

∆133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling.

Campbell H, Fleming N, Roth I, Mehta S, Wiles A, Williams G, Vennin C, Arsic N, Parkin A, Pajic M, Munro F, McNoe L, Black M, McCall J, Slatter TL, Timpson P, Reddel R, Roux P, Print C, Baird MA, Braithwaite AW.

Nat Commun. 2018 Jan 17;9(1):254. doi: 10.1038/s41467-017-02408-0.

9.

Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosis.

Renshall L, Arnold N, West L, Braithwaite A, Pickworth J, Walker R, Alfaidi M, Chamberlain J, Casbolt H, Thompson AAR, Holt C, Iglarz M, Francis S, Lawrie A.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217752328. doi: 10.1177/2045893217752328. Epub 2017 Dec 20.

10.

Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.

Kazantseva M, Hung NA, Mehta S, Roth I, Eiholzer R, Rich AM, Seo B, Baird MA, Braithwaite AW, Slatter TL.

Sci Rep. 2017 May 8;7(1):1566. doi: 10.1038/s41598-017-01800-6.

11.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

12.

A Study of TP53 RNA Splicing Illustrates Pitfalls of RNA-seq Methodology.

Mehta S, Tsai P, Lasham A, Campbell H, Reddel R, Braithwaite A, Print C.

Cancer Res. 2016 Dec 15;76(24):7151-7159. Epub 2016 Oct 20.

13.

Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.

Slatter TL, Wilson M, Tang C, Campbell HG, Ward VK, Young VL, Van Ly D, Fleming NI, Braithwaite AW, Baird MA.

Oncoimmunology. 2015 Dec 17;5(3):e1112941. eCollection 2016 Mar.

14.

A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.

Lasham A, Mehta SY, Fitzgerald SJ, Woolley AG, Hearn JI, Hurley DG, Ruza I, Algie M, Shelling AN, Braithwaite AW, Print CG.

Int J Cancer. 2016 Sep 1;139(5):1157-70. doi: 10.1002/ijc.30137. Epub 2016 May 26.

15.

HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.

Dasgupta T, Antony J, Braithwaite AW, Horsfield JA.

J Biol Chem. 2016 Jun 10;291(24):12761-70. doi: 10.1074/jbc.M115.704627. Epub 2016 Apr 12.

16.

The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Roth I, Campbell H, Rubio C, Vennin C, Wilson M, Wiles A, Williams G, Woolley A, Timpson P, Berridge MV, Fleming N, Baird M, Braithwaite AW.

Oncogene. 2016 Sep 22;35(38):4981-9. doi: 10.1038/onc.2016.45. Epub 2016 Mar 21.

PMID:
26996665
17.

17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.

Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE.

ACS Chem Neurosci. 2016 Mar 16;7(3):297-304. doi: 10.1021/acschemneuro.5b00245. Epub 2016 Jan 8.

18.

Telomere length and periodontal attachment loss: a prospective cohort study.

Thomson WM, Zeng J, Broadbent JM, Foster Page LA, Shalev I, Moffitt TE, Caspi A, Williams SM, Braithwaite AW, Robertson SP, Poulton R.

J Clin Periodontol. 2016 Feb;43(2):121-7. doi: 10.1111/jcpe.12499. Epub 2016 Feb 19.

19.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T.

Cancer Res. 2015 Dec 1;75(23):5143-54. doi: 10.1158/0008-5472.CAN-15-0423. Epub 2015 Oct 15.

20.

Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant.

Slatter TL, Hung N, Bowie S, Campbell H, Rubio C, Speidel D, Wilson M, Baird M, Royds JA, Braithwaite AW.

Cell Death Dis. 2015 Jun 11;6:e1783. doi: 10.1038/cddis.2015.149.

21.

Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a ∆133p53α mimic.

Sawhney S, Hood K, Shaw A, Braithwaite AW, Stubbs R, Hung NA, Royds JA, Slatter TL.

PLoS One. 2015 Feb 2;10(2):e0116270. doi: 10.1371/journal.pone.0116270. eCollection 2015.

22.

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.

Eur J Pharmacol. 2014 Aug 5;736:124-30. doi: 10.1016/j.ejphar.2014.04.041. Epub 2014 May 8.

23.

Increased paired box transcription factor 8 has a survival function in glioma.

Hung N, Chen YJ, Taha A, Olivecrona M, Boet R, Wiles A, Warr T, Shaw A, Eiholzer R, Baguley BC, Eccles MR, Braithwaite AW, Macfarlane M, Royds JA, Slatter T.

BMC Cancer. 2014 Mar 6;14:159. doi: 10.1186/1471-2407-14-159.

24.

Internalizing disorders and leukocyte telomere erosion: a prospective study of depression, generalized anxiety disorder and post-traumatic stress disorder.

Shalev I, Moffitt TE, Braithwaite AW, Danese A, Fleming NI, Goldman-Mellor S, Harrington HL, Houts RM, Israel S, Poulton R, Robertson SP, Sugden K, Williams B, Caspi A.

Mol Psychiatry. 2014 Nov;19(11):1163-70. doi: 10.1038/mp.2013.183. Epub 2014 Jan 14.

25.

CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients.

Horswell SD, Fryer LG, Hutchison CE, Zindrou D, Speedy HE, Town MM, Duncan EJ, Sivapackianathan R, Patel HN, Jones EL, Braithwaite A, Salm MP, Neuwirth CK, Potter E, Anderson JR, Taylor KM, Seed M, Betteridge DJ, Crook MA, Wierzbicki AS, Scott J, Naoumova RP, Shoulders CC.

J Lipid Res. 2013 Dec;54(12):3491-505. doi: 10.1194/jlr.M041814. Epub 2013 Oct 8.

26.

Stimulating p53 down-under: a report from the 1st Australian p53 Workshop.

Neilsen PM, Braithwaite AW, Gamell C, Haupt S, Janic A, Strasser A, Wolyniec K, Haupt Y.

Cell Death Differ. 2013 Dec;20(12):1753-6. doi: 10.1038/cdd.2013.2. Epub 2013 Feb 1. No abstract available.

27.

The mesenchymal architecture of the cranial mesoderm of mouse embryos is disrupted by the loss of Twist1 function.

Bildsoe H, Loebel DA, Jones VJ, Hor AC, Braithwaite AW, Chen YT, Behringer RR, Tam PP.

Dev Biol. 2013 Feb 15;374(2):295-307. doi: 10.1016/j.ydbio.2012.12.004. Epub 2012 Dec 19.

28.

YB-1: oncoprotein, prognostic marker and therapeutic target?

Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW.

Biochem J. 2013 Jan 1;449(1):11-23. doi: 10.1042/BJ20121323. Review.

PMID:
23216250
29.

Enhanced isolation of fibroblasts from human skin explants.

Huschtscha LI, Napier CE, Noble JR, Bower K, Au AY, Campbell HG, Braithwaite AW, Reddel RR.

Biotechniques. 2012 Oct;53(4):239-44. doi: 10.2144/0000113939.

PMID:
23046507
30.

6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.

Yuan Y, Stevens DL, Braithwaite A, Scoggins KL, Bilsky EJ, Akbarali HI, Dewey WL, Zhang Y.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4731-4. doi: 10.1016/j.bmcl.2012.05.075. Epub 2012 May 26.

31.

Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD).

Campbell HG, Mehta R, Neumann AA, Rubio C, Baird M, Slatter TL, Braithwaite AW.

Oncogene. 2013 Feb 14;32(7):827-36. doi: 10.1038/onc.2012.102. Epub 2012 Apr 9.

PMID:
22484427
32.

Does Δ133p53 isoform trigger inflammation and autoimmunity?

Campbell HG, Slatter TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW.

Cell Cycle. 2012 Feb 1;11(3):446-50. doi: 10.4161/cc.11.3.19054. Epub 2012 Feb 1.

PMID:
22262184
33.

YB-1, the E2F pathway, and regulation of tumor cell growth.

Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW.

J Natl Cancer Inst. 2012 Jan 18;104(2):133-46. doi: 10.1093/jnci/djr512. Epub 2011 Dec 28.

34.

[Cyclic vomiting in association with chronic cannabis abuse].

Del Val A, Braithwaite A, Blé M, Nos P.

Med Clin (Barc). 2012 Jun 2;139(1):42. doi: 10.1016/j.medcli.2011.09.016. Epub 2011 Nov 8. Spanish. No abstract available.

PMID:
22075228
35.

The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.

Royds JA, Al Nadaf S, Wiles AK, Chen YJ, Ahn A, Shaw A, Bowie S, Lam F, Baguley BC, Braithwaite AW, MacFarlane MR, Hung NA, Slatter TL.

PLoS One. 2011;6(10):e26737. doi: 10.1371/journal.pone.0026737. Epub 2011 Oct 26.

36.

Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function.

McDermott-Roe C, Ye J, Ahmed R, Sun XM, Serafín A, Ware J, Bottolo L, Muckett P, Cañas X, Zhang J, Rowe GC, Buchan R, Lu H, Braithwaite A, Mancini M, Hauton D, Martí R, García-Arumí E, Hubner N, Jacob H, Serikawa T, Zidek V, Papousek F, Kolar F, Cardona M, Ruiz-Meana M, García-Dorado D, Comella JX, Felkin LE, Barton PJ, Arany Z, Pravenec M, Petretto E, Sanchis D, Cook SA.

Nature. 2011 Oct 5;478(7367):114-8. doi: 10.1038/nature10490.

37.

Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression.

Joshi S, Braithwaite AW, Robinson PJ, Chircop M.

Mol Cancer. 2011 Jun 28;10:78. doi: 10.1186/1476-4598-10-78.

38.

Prognostic association of YB-1 expression in breast cancers: a matter of antibody.

Woolley AG, Algie M, Samuel W, Harfoot R, Wiles A, Hung NA, Tan PH, Hains P, Valova VA, Huschtscha L, Royds JA, Perez D, Yoon HS, Cohen SB, Robinson PJ, Bay BH, Lasham A, Braithwaite AW.

PLoS One. 2011;6(6):e20603. doi: 10.1371/journal.pone.0020603. Epub 2011 Jun 10.

39.

PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein.

Li CG, Nyman JE, Braithwaite AW, Eccles MR.

Oncogene. 2011 Dec 1;30(48):4824-34. doi: 10.1038/onc.2011.190. Epub 2011 May 23.

40.

Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform.

Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, Williams G, Wilson M, Engelmann A, Jeffs A, Royds JA, Baird MA, Braithwaite AW.

Blood. 2011 May 12;117(19):5166-77. doi: 10.1182/blood-2010-11-321851. Epub 2011 Mar 16.

41.

Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.

Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT, Ogholikhan S, Aigner R, Winkler J, Farrer MJ, Gage FH.

Neurobiol Dis. 2011 Mar;41(3):706-16. doi: 10.1016/j.nbd.2010.12.008. Epub 2010 Dec 16.

42.
43.

Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukhman A, Yu X, Castanedes-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ.

Neurobiol Dis. 2010 Dec;40(3):503-17. doi: 10.1016/j.nbd.2010.07.010. Epub 2010 Jul 24.

44.

The dynamin inhibitors MiTMAB and OcTMAB induce cytokinesis failure and inhibit cell proliferation in human cancer cells.

Joshi S, Perera S, Gilbert J, Smith CM, Mariana A, Gordon CP, Sakoff JA, McCluskey A, Robinson PJ, Braithwaite AW, Chircop M.

Mol Cancer Ther. 2010 Jul;9(7):1995-2006. doi: 10.1158/1535-7163.MCT-10-0161. Epub 2010 Jun 22.

45.

Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen.

Dale BM, Braithwaite AC, Boll DT, Merkle EM.

Invest Radiol. 2010 Feb;45(2):104-8. doi: 10.1097/RLI.0b013e3181c8ceac.

PMID:
20027117
46.

Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing.

Cohen SB, Ma W, Valova VA, Algie M, Harfoot R, Woolley AG, Robinson PJ, Braithwaite AW.

Oncogene. 2010 Jan 21;29(3):403-10. doi: 10.1038/onc.2009.321. Epub 2009 Oct 19.

PMID:
19838214
47.

p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors.

Slatter TL, Ganesan P, Holzhauer C, Mehta R, Rubio C, Williams G, Wilson M, Royds JA, Baird MA, Braithwaite AW.

Cell Death Differ. 2010 Mar;17(3):540-50. doi: 10.1038/cdd.2009.136. Epub 2009 Sep 25.

48.

Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21(WAF1/CIP1).

Huschtscha LI, Moore JD, Noble JR, Campbell HG, Royds JA, Braithwaite AW, Reddel RR.

J Cell Sci. 2009 Aug 15;122(Pt 16):2989-95. doi: 10.1242/jcs.044107. Epub 2009 Jul 28.

49.

Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells.

Hibma MH, Real NC, Wiles A, Dobson-Le D, Dix BR, Wynford-Thomas D, Braithwaite AW, Royds JA.

Virus Res. 2009 Oct;145(1):112-20. doi: 10.1016/j.virusres.2009.06.016. Epub 2009 Jul 2.

PMID:
19576936
50.

Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms.

Hancox RJ, Poulton R, Welch D, Olova N, McLachlan CR, Greene JM, Sears MR, Caspi A, Moffitt TE, Robertson SP, Braithwaite AW.

Hum Genet. 2009 Oct;126(4):559-65. doi: 10.1007/s00439-009-0704-z. Epub 2009 Jun 12.

Supplemental Content

Loading ...
Support Center